There will be blood, downhome poetry and mystical light. August Wilson’s “Joe Turner’s Come and Gone” runs through June 21 in a staggering, must-see production at St. Paul’s Penumbra Theatre, where ...

Boston Scientific is spending $14.5 billion in cash and stock to buy Penumbra, another medical-device maker that makes products used in minimally invasive procedures to treat conditions such as blood ...

ALAMEDA, Calif. (AP) — ALAMEDA, Calif. (AP) — Penumbra Inc. (PEN) on Wednesday reported first-quarter net income of $32.6 million. On a per-share basis, the Alameda, California-based company said it ...

Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the first quarter ended March 31, 2026.

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min A Boston Scientific exec told ...

While the experiences of African-Americans don’t find their way onto Broadway stages very often, St. Paul’s Penumbra Theatre has made telling such stories the core of its mission for a half-century ...

Penumbra has rolled out its first new system since Boston Scientific announced plans to acquire the company in a $14.5 billion cash and stock deal. The company has launched its Lightning Flash 3.0 ...

During Boston Scientific chief executive Mike Mahoney’s 13-year tenure, he has presided over more than 40 acquisitions so far. But this one is different, at least by size: Mahoney on Thursday unveiled ...

Boston Scientific’s last mega-deal didn’t go so well. The medtech company with a large Minnesota presence acquired Arden Hills’ Guidant for $27 billion in 2006. This triggered years of legal ...

Penumbra expected to generate $1.4 bln in 2025 sales; shares surge 12% Transaction values Penumbra at $374 per share, 19.3% premium to last close Penumbra CEO Adam Elsesser to join Boston Scientific's ...

Boston Scientific said on Thursday it will buy ⁠medtech firm Penumbra in a deal valued at about $14.5 billion to expand its portfolio of cardiovascular devices, in the largest acquisition by the ...

Boston Scientific (BSX) on Thursday announced a definitive agreement to acquire Penumbra (PEN) in a cash and stock transaction that values the Alameda-based heart device maker at ~$14.5B, including ...